{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:30:19Z","timestamp":1793053819952,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:00:00Z","timestamp":1750464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:00:00Z","timestamp":1750464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-C-048"],"award-info":[{"award-number":["2022-PUMCH-C-048"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-A-051"],"award-info":[{"award-number":["2022-PUMCH-A-051"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2023-I2M-C&T-B-016"],"award-info":[{"award-number":["2023-I2M-C&T-B-016"]}]},{"name":"Development Center for Medical Science & Technology National Health Commission of the People's Republic of China","award":["WKZX2024CX102214"],"award-info":[{"award-number":["WKZX2024CX102214"]}]},{"name":"CSPEN Project Management Committee","award":["Z-2017-24-2403"],"award-info":[{"award-number":["Z-2017-24-2403"]}]},{"DOI":"10.13039\/100016966","name":"Bethune Charitable Foundation","doi-asserted-by":"publisher","award":["STLKY2-139"],"award-info":[{"award-number":["STLKY2-139"]}],"id":[{"id":"10.13039\/100016966","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2024ZD0520600"],"award-info":[{"award-number":["2024ZD0520600"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"DOI":"10.1186\/s12935-025-03878-9","type":"journal-article","created":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T12:09:20Z","timestamp":1750507760000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comprehensive analysis of single-cell and bulk RNA sequencing data unveils antigen-presenting and processing fibroblasts and establishes a predictive model in gastric cancer"],"prefix":"10.1186","volume":"25","author":[{"given":"Chenggang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangqi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixuan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zicheng","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanmo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiming","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,21]]},"reference":[{"key":"3878_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"3878_CR2","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","volume":"396","author":"EC Smyth","year":"2020","unstructured":"Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396:635\u201348.","journal-title":"Lancet"},{"key":"3878_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13045-023-01451-3","volume":"16","author":"WL Guan","year":"2023","unstructured":"Guan WL, He Y, Xu RH. Gastric cancer treatment: recent progress and future perspectives. J Hematol Oncol. 2023;16:57.","journal-title":"J Hematol Oncol"},{"key":"3878_CR4","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1093\/annonc\/mdw168","volume":"27","author":"JM Pitt","year":"2016","unstructured":"Pitt JM, Marabelle A, Eggermont A, Soria JC, Kroemer G, Zitvogel L. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Ann Oncol. 2016;27:1482\u201392.","journal-title":"Ann Oncol"},{"key":"3878_CR5","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41392-020-00449-4","volume":"6","author":"T Tang","year":"2021","unstructured":"Tang T, Huang X, Zhang G, Hong Z, Bai X, Liang T. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. Signal Transduct Target Ther. 2021;6:72.","journal-title":"Signal Transduct Target Ther"},{"key":"3878_CR6","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1158\/2159-8290.CD-19-1384","volume":"10","author":"Y Kieffer","year":"2020","unstructured":"Kieffer Y, Hocine HR, Gentric G, Pelon F, Bernard C, Bourachot B, et al. Single-Cell analysis reveals fibroblast clusters linked to immunotherapy resistance in Cancer. Cancer Discov. 2020;10:1330\u201351.","journal-title":"Cancer Discov"},{"key":"3878_CR7","doi-asserted-by":"crossref","unstructured":"Wang H, Liang Y, Liu Z, Zhang R, Chao J, Wang M et al. POSTN(+) cancer-associated fibroblasts determine the efficacy of immunotherapy in hepatocellular carcinoma. J Immunother Cancer. 2024; 12.","DOI":"10.1136\/jitc-2023-008721"},{"key":"3878_CR8","doi-asserted-by":"publisher","first-page":"e1515","DOI":"10.1002\/ctm2.1515","volume":"13","author":"C Chen","year":"2023","unstructured":"Chen C, Guo Q, Liu Y, Hou Q, Liao M, Guo Y, et al. Single-cell and Spatial transcriptomics reveal POSTN(+) cancer-associated fibroblasts correlated with immune suppression and tumour progression in non-small cell lung cancer. Clin Transl Med. 2023;13:e1515.","journal-title":"Clin Transl Med"},{"key":"3878_CR9","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/s41577-021-00540-z","volume":"21","author":"S Davidson","year":"2021","unstructured":"Davidson S, Coles M, Thomas T, Kollias G, Ludewig B, Turley S, et al. Fibroblasts as immune regulators in infection, inflammation and cancer. Nat Rev Immunol. 2021;21:704\u201317.","journal-title":"Nat Rev Immunol"},{"key":"3878_CR10","doi-asserted-by":"publisher","first-page":"eadj5705","DOI":"10.1126\/scitranslmed.adj5705","volume":"16","author":"G Fan","year":"2024","unstructured":"Fan G, Yu B, Tang L, Zhu R, Chen J, Zhu Y, et al. TSPAN8(+) myofibroblastic cancer-associated fibroblasts promote chemoresistance in patients with breast cancer. Sci Transl Med. 2024;16:eadj5705.","journal-title":"Sci Transl Med"},{"key":"3878_CR11","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/nrc.2016.73","volume":"16","author":"R Kalluri","year":"2016","unstructured":"Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016;16:582\u201398.","journal-title":"Nat Rev Cancer"},{"key":"3878_CR12","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.cell.2020.03.053","volume":"181","author":"O Rozenblatt-Rosen","year":"2020","unstructured":"Rozenblatt-Rosen O, Regev A, Oberdoerffer P, Nawy T, Hupalowska A, Rood JE, et al. The human tumor atlas network: charting tumor transitions across space and time at Single-Cell resolution. Cell. 2020;181:236\u201349.","journal-title":"Cell"},{"key":"3878_CR13","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1158\/2159-8290.CD-19-0094","volume":"9","author":"E Elyada","year":"2019","unstructured":"Elyada E, Bolisetty M, Laise P, Flynn WF, Courtois ET, Burkhart RA, et al. Cross-Species Single-Cell analysis of pancreatic ductal adenocarcinoma reveals Antigen-Presenting Cancer-Associated fibroblasts. Cancer Discov. 2019;9:1102\u201323.","journal-title":"Cancer Discov"},{"key":"3878_CR14","doi-asserted-by":"crossref","unstructured":"Kerdidani D, Aerakis E, Verrou KM, Angelidis I, Douka K, Maniou MA et al. Lung tumor MHCII immunity depends on in situ antigen presentation by fibroblasts. J Exp Med. 2022; 219.","DOI":"10.1084\/jem.20210815"},{"key":"3878_CR15","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.ccell.2022.04.011","volume":"40","author":"H Huang","year":"2022","unstructured":"Huang H, Wang Z, Zhang Y, Pradhan RN, Ganguly D, Chandra R, et al. Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer. Cancer Cell. 2022;40:656\u2013e673657.","journal-title":"Cancer Cell"},{"key":"3878_CR16","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1158\/1078-0432.CCR-22-1031","volume":"29","author":"KB Kennel","year":"2023","unstructured":"Kennel KB, Bozlar M, De Valk AF, Greten FR. Cancer-Associated fibroblasts in inflammation and antitumor immunity. Clin Cancer Res. 2023;29:1009\u201316.","journal-title":"Clin Cancer Res"},{"key":"3878_CR17","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/cac2.12078","volume":"40","author":"S Ding","year":"2020","unstructured":"Ding S, Chen X, Shen K. Single-cell RNA sequencing in breast cancer: Understanding tumor heterogeneity and paving roads to individualized therapy. Cancer Commun (Lond). 2020;40:329\u201344.","journal-title":"Cancer Commun (Lond)"},{"key":"3878_CR18","doi-asserted-by":"publisher","first-page":"7338","DOI":"10.1038\/s41467-021-27619-4","volume":"12","author":"CHL K\u00fcrten","year":"2021","unstructured":"K\u00fcrten CHL, Kulkarni A, Cillo AR, Santos PM, Roble AK, Onkar S, et al. Investigating immune and non-immune cell interactions in head and neck tumors by single-cell RNA sequencing. Nat Commun. 2021;12:7338.","journal-title":"Nat Commun"},{"key":"3878_CR19","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.7150\/thno.92336","volume":"14","author":"T Zhang","year":"2024","unstructured":"Zhang T, Zhao F, Lin Y, Liu M, Zhou H, Cui F, et al. Integrated analysis of single-cell and bulk transcriptomics develops a robust neuroendocrine cell-intrinsic signature to predict prostate cancer progression. Theranostics. 2024;14:1065\u201380.","journal-title":"Theranostics"},{"key":"3878_CR20","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12967-023-04056-z","volume":"21","author":"Z Tan","year":"2023","unstructured":"Tan Z, Chen X, Zuo J, Fu S, Wang H, Wang J. Comprehensive analysis of scRNA-Seq and bulk RNA-Seq reveals dynamic changes in the tumor immune microenvironment of bladder cancer and establishes a prognostic model. J Transl Med. 2023;21:223.","journal-title":"J Transl Med"},{"key":"3878_CR21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12967-023-04807-y","volume":"22","author":"W Wang","year":"2024","unstructured":"Wang W, Li T, Xie Z, Zhao J, Zhang Y, Ruan Y, et al. Integrating single-cell and bulk RNA sequencing data unveils antigen presentation and process-related CAFS and establishes a predictive signature in prostate cancer. J Transl Med. 2024;22:57.","journal-title":"J Transl Med"},{"key":"3878_CR22","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/s41568-023-00549-7","volume":"23","author":"M Tsoumakidou","year":"2023","unstructured":"Tsoumakidou M. The advent of immune stimulating CAFs in cancer. Nat Rev Cancer. 2023;23:258\u201369.","journal-title":"Nat Rev Cancer"},{"key":"3878_CR23","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.csbj.2024.02.002","volume":"23","author":"J Li","year":"2024","unstructured":"Li J, Yu T, Sun J, Ma M, Zheng Z, Kang W, et al. Comprehensive integration of single-cell RNA and transcriptome RNA sequencing to Establish a pyroptosis-related signature for improving prognostic prediction of gastric cancer. Comput Struct Biotechnol J. 2024;23:990\u20131004.","journal-title":"Comput Struct Biotechnol J"},{"key":"3878_CR24","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1002\/cac2.12311","volume":"42","author":"W Zhang","year":"2022","unstructured":"Zhang W, Zhang Q, Yang N, Shi Q, Su H, Lin T, et al. Crosstalk between IL-15R\u03b1(+) tumor-associated macrophages and breast cancer cells reduces CD8(+) T cell recruitment. Cancer Commun (Lond). 2022;42:536\u201357.","journal-title":"Cancer Commun (Lond)"},{"key":"3878_CR25","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41568-021-00366-w","volume":"21","author":"D Bayik","year":"2021","unstructured":"Bayik D, Lathia JD. Cancer stem cell-immune cell crosstalk in tumour progression. Nat Rev Cancer. 2021;21:526\u201336.","journal-title":"Nat Rev Cancer"},{"key":"3878_CR26","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12943-020-01165-x","volume":"19","author":"H Yang","year":"2020","unstructured":"Yang H, Zhang Q, Xu M, Wang L, Chen X, Feng Y, et al. CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis. Mol Cancer. 2020;19:41.","journal-title":"Mol Cancer"},{"key":"3878_CR27","doi-asserted-by":"crossref","unstructured":"Zhu X, Liang R, Lan T, Ding D, Huang S, Shao J et al. Tumor-associated macrophage-specific CD155 contributes to M2-phenotype transition, immunosuppression, and tumor progression in colorectal cancer. J Immunother Cancer. 2022; 10.","DOI":"10.1136\/jitc-2021-004219"},{"key":"3878_CR28","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha SY, Oh DY, Ya\u00f1ez P, Bai Y, Ryu MH, Lee J, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24:1181\u201395.","journal-title":"Lancet Oncol"},{"key":"3878_CR29","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/s12885-025-13591-5","volume":"25","author":"H Hirano","year":"2025","unstructured":"Hirano H, Takahashi N, Amanuma Y, Suzuki N, Takahari D, Kawakami T, et al. Phase II trial of nab-paclitaxel plus ramucirumab in combination with nivolumab for unresectable advanced or recurrent gastric cancer after progression on first-line treatment including fluoropyrimidine, platinum, and anti-PD-1\/PD-L1 antibody (PADDLE). BMC Cancer. 2025;25:201.","journal-title":"BMC Cancer"},{"key":"3878_CR30","doi-asserted-by":"crossref","unstructured":"Takei S, Kawazoe A, Shitara K. The new era of immunotherapy in gastric Cancer. Cancers (Basel). 2022; 14.","DOI":"10.3390\/cancers14041054"},{"key":"3878_CR31","doi-asserted-by":"publisher","first-page":"4309","DOI":"10.1158\/1078-0432.CCR-16-0903","volume":"22","author":"RM Chabanon","year":"2016","unstructured":"Chabanon RM, Pedrero M, Lefebvre C, Marabelle A, Soria JC, Postel-Vinay S. Mutational landscape and sensitivity to immune checkpoint blockers. Clin Cancer Res. 2016;22:4309\u201321.","journal-title":"Clin Cancer Res"},{"key":"3878_CR32","doi-asserted-by":"publisher","first-page":"188615","DOI":"10.1016\/j.bbcan.2021.188615","volume":"1876","author":"K Li","year":"2021","unstructured":"Li K, Zhang A, Li X, Zhang H, Zhao L. Advances in clinical immunotherapy for gastric cancer. Biochim Biophys Acta Rev Cancer. 2021;1876:188615.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"3878_CR33","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.3390\/curroncol29030131","volume":"29","author":"A H\u00f6gner","year":"2022","unstructured":"H\u00f6gner A, Moehler M. Immunotherapy in gastric Cancer. Curr Oncol. 2022;29:1559\u201374.","journal-title":"Curr Oncol"},{"key":"3878_CR34","doi-asserted-by":"publisher","first-page":"948647","DOI":"10.3389\/fimmu.2022.948647","volume":"13","author":"X Jin","year":"2022","unstructured":"Jin X, Liu Z, Yang D, Yin K, Chang X. Recent progress and future perspectives of immunotherapy in advanced gastric Cancer. Front Immunol. 2022;13:948647.","journal-title":"Front Immunol"},{"key":"3878_CR35","doi-asserted-by":"publisher","first-page":"1285343","DOI":"10.3389\/fphar.2023.1285343","volume":"14","author":"K Liu","year":"2023","unstructured":"Liu K, Yuan S, Wang C, Zhu H. Resistance to immune checkpoint inhibitors in gastric cancer. Front Pharmacol. 2023;14:1285343.","journal-title":"Front Pharmacol"},{"key":"3878_CR36","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/cac2.12516","volume":"44","author":"FH Wang","year":"2024","unstructured":"Wang FH, Zhang XT, Tang L, Wu Q, Cai MY, Li YF, et al. The Chinese society of clinical oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2023. Cancer Commun (Lond). 2024;44:127\u201372.","journal-title":"Cancer Commun (Lond)"},{"key":"3878_CR37","doi-asserted-by":"publisher","first-page":"1016817","DOI":"10.3389\/fimmu.2022.1016817","volume":"13","author":"Y Liu","year":"2022","unstructured":"Liu Y, Li C, Lu Y, Liu C, Yang W. Tumor microenvironment-mediated immune tolerance in development and treatment of gastric cancer. Front Immunol. 2022;13:1016817.","journal-title":"Front Immunol"},{"key":"3878_CR38","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.trecan.2024.03.008","volume":"10","author":"T Yasuda","year":"2024","unstructured":"Yasuda T, Wang YA. Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development. Trends Cancer. 2024;10:627\u201342.","journal-title":"Trends Cancer"},{"key":"3878_CR39","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1038\/s41467-024-46769-9","volume":"15","author":"D Maggiorani","year":"2024","unstructured":"Maggiorani D, Le O, Lisi V, Landais S, Moquin-Beaudry G, Lavall\u00e9e VP, et al. Senescence drives immunotherapy resistance by inducing an immunosuppressive tumor microenvironment. Nat Commun. 2024;15:2435.","journal-title":"Nat Commun"},{"key":"3878_CR40","doi-asserted-by":"publisher","first-page":"784","DOI":"10.3389\/fimmu.2020.00784","volume":"11","author":"F Petitprez","year":"2020","unstructured":"Petitprez F, Meylan M, de Reyni\u00e8s A, Saut\u00e8s-Fridman C, Fridman WH. The tumor microenvironment in the response to immune checkpoint Blockade therapies. Front Immunol. 2020;11:784.","journal-title":"Front Immunol"},{"key":"3878_CR41","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12943-023-01860-5","volume":"22","author":"H Zhang","year":"2023","unstructured":"Zhang H, Yue X, Chen Z, Liu C, Wu W, Zhang N, et al. Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials. Mol Cancer. 2023;22:159.","journal-title":"Mol Cancer"},{"key":"3878_CR42","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.ccell.2018.01.011","volume":"33","author":"A Costa","year":"2018","unstructured":"Costa A, Kieffer Y, Scholer-Dahirel A, Pelon F, Bourachot B, Cardon M, et al. Fibroblast heterogeneity and immunosuppressive environment in human breast Cancer. Cancer Cell. 2018;33:463\u2013e479410.","journal-title":"Cancer Cell"},{"key":"3878_CR43","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","volume":"20","author":"X Mao","year":"2021","unstructured":"Mao X, Xu J, Wang W, Liang C, Hua J, Liu J, et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer. 2021;20:131.","journal-title":"Mol Cancer"},{"key":"3878_CR44","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 Blockade in non-small cell lung cancer. Science. 2015;348:124\u20138.","journal-title":"Science"},{"key":"3878_CR45","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","volume":"9","author":"ZR Chalmers","year":"2017","unstructured":"Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9:34.","journal-title":"Genome Med"},{"key":"3878_CR46","doi-asserted-by":"publisher","first-page":"834934","DOI":"10.3389\/fonc.2022.834934","volume":"12","author":"X Zhu","year":"2022","unstructured":"Zhu X, Su T, Wang S, Zhou H, Shi W. New advances in Nano-Drug delivery systems: Helicobacter pylori and gastric Cancer. Front Oncol. 2022;12:834934.","journal-title":"Front Oncol"},{"key":"3878_CR47","doi-asserted-by":"crossref","unstructured":"Doughty ACV, Hoover AR, Layton E, Murray CK, Howard EW, Chen WR. Nanomaterial applications in photothermal therapy for Cancer. Mater (Basel). 2019; 12.","DOI":"10.3390\/ma12050779"},{"key":"3878_CR48","doi-asserted-by":"crossref","unstructured":"Rai A, Noor S, Ahmad SI, Alajmi MF, Hussain A, Abbas H et al. Recent advances and implication of bioengineered nanomaterials in Cancer theranostics. Med (Kaunas). 2021; 57.","DOI":"10.3390\/medicina57020091"},{"key":"3878_CR49","doi-asserted-by":"publisher","first-page":"6777","DOI":"10.1021\/acs.jmedchem.1c00050","volume":"64","author":"J Zhang","year":"2021","unstructured":"Zhang J, Jiang M, Li S, Zhang Z, Sun H, Yang F, et al. Developing a novel anticancer Gold(III) agent to integrate chemotherapy and immunotherapy. J Med Chem. 2021;64:6777\u201391.","journal-title":"J Med Chem"},{"key":"3878_CR50","doi-asserted-by":"publisher","first-page":"434","DOI":"10.7150\/thno.67300","volume":"12","author":"B Ji","year":"2022","unstructured":"Ji B, Wei M, Yang B. Recent advances in nanomedicines for photodynamic therapy (PDT)-driven cancer immunotherapy. Theranostics. 2022;12:434\u201358.","journal-title":"Theranostics"},{"key":"3878_CR51","doi-asserted-by":"publisher","first-page":"101098","DOI":"10.1016\/j.drup.2024.101098","volume":"75","author":"Z Xu","year":"2024","unstructured":"Xu Z, Zhou H, Li T, Yi Q, Thakur A, Zhang K, et al. Application of biomimetic nanovaccines in cancer immunotherapy: A useful strategy to help combat immunotherapy resistance. Drug Resist Updat. 2024;75:101098.","journal-title":"Drug Resist Updat"},{"key":"3878_CR52","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12885-022-10332-w","volume":"23","author":"Z Zhou","year":"2023","unstructured":"Zhou Z, Guo S, Lai S, Wang T, Du Y, Deng J, et al. Integrated single-cell and bulk RNA sequencing analysis identifies a cancer-associated fibroblast-related gene signature for predicting survival and therapy in gastric cancer. BMC Cancer. 2023;23:108.","journal-title":"BMC Cancer"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-025-03878-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-025-03878-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-025-03878-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T13:02:23Z","timestamp":1750510943000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/s12935-025-03878-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,21]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3878"],"URL":"https:\/\/doi.org\/10.1186\/s12935-025-03878-9","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,21]]},"assertion":[{"value":"11 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Peking Union Medical College Hospital and the approval number is XHDW-2024-89. Informed consent was obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"225"}}